The use of trametinib (Megenin) in specific circumstances requires careful instructions

Trametinib is a highly selective MEK inhibitor that inhibits the proliferation and survival of tumor cells mainly by blocking the MAPK/ERK signaling pathway. It is often used in combination with dabrafenib to treat BRAF. V600mutated melanoma and some patients with non-small cell lung cancer. Despite its remarkable efficacy, trametinib may cause multi-system adverse reactions, especially toxicity in the heart, eyes, lungs and other organs due to its effect on key signaling pathways related to cell proliferation. Therefore, extreme caution is required when using it in specific populations or under specific pathological conditions to ensure a balance between efficacy and safety.

Trametinib can cause a decrease in left ventricular ejection fraction (LVEF) and the risk of heart failure, especially in patients with a history of heart disease, arrhythmia, or hypertension. Clinical studies have shown that some patients develop symptoms of decreased cardiac function or even congestive heart failure in the early stages of treatment. Therefore, patients with impaired cardiac function should undergo baseline cardiac ultrasound examination before starting medication and regularly monitor LVEF changes during treatment. If a significant decrease is detected, treatment should be interrupted immediately or the dose should be reduced, and continued use should be considered after cardiac function has recovered.

Trametinib is associated with serious ocular adverse events such as retinal pigment epithelial detachment (RPED) and retinal vein occlusion (RVO). Patients with pre-existing glaucoma, diabetic retinopathy, or other ocular vascular disease should receive a comprehensive eye examination prior to use. If blurred vision, eye pain or visual field loss occurs during treatment, the medication should be stopped immediately and seek medical attention. If RVO or other serious eye disease is diagnosed, trametinib treatment should be permanently stopped to avoid irreversible damage to visual function.

In addition to heart and eye problems, trametinib should be used with caution in people with lung disease, infections, and pregnancy. This drug may induce interstitial lung disease (ILD) or pneumonia, especially in people with limited lung function or a history of smoking. Once persistent cough, dyspnea or chest pain occurs, the drug should be discontinued and evaluated in time. Trametinib is contraindicated in female patients during pregnancy and lactation because animal experiments suggest that it may cause abnormal embryonic development. In addition, when taking drugs together, attention should be paid to drug-drug interactions and avoid simultaneous use with strong CYP3A4 inhibitors or inducers to prevent changes in pharmacokinetics that increase the risk of toxicity.

Reference materials:https://www.drugs.com/